Business Standard

Dr Reddy's Lab rises 2.3%

Read more on:    Nordic Bioscience | Dr Reddys Lab
Related News

The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters.

The company which conducted the study to determine the efficacy and safety of the drug, with Rheoscience — a subsidiary of said, it met its primary endpoint of reducing HbA1c or Glycoslated haemoglobin molecule, which indicates glucose level in blood. Besides, the oral anti-diabetic drug also showed effective results on fasting plasma glucose, oedeman and weight gain & body composition.

Read more on:   
|

Quick Links

 

Market News

JSW steel hits a brief pause

The company has been doing well despite challenges on the iron-ore availability

Zinc down 0.3% on overseas cues

Metal for delivery in May fell 0.28%

Mentha oil up 0.1% on pick-up in demand

Oil for delivery in April edged up by 0.08%

Crude palm oil down 0.1% on subdued demand

Oil for delivery in May shed 0.09%

Copper down 0.2% on weak Asian cues

Metal for delivery in June shed 0.19%

Back to Top